Vigo is pleased to have supported Elevara Medicines on its successful launch, including a $70m Series A financing to advance its lead programme into Phase 2 clinical trials in rheumatoid arthritis and to expand its pipeline into other chronic inflammatory and women’s health conditions.
Vigo is pleased to have supported Elevara Medicines on its successful launch, including a $70m Series A financing to advance its lead programme into Phase 2 clinical trials in rheumatoid arthritis and to expand its pipeline into other chronic inflammatory and women’s health conditions.